Pramlintide 5mg
Synthetic amylin analogue evaluated in metabolic models for delayed gastric emptying, postprandial glucose stability, and satiety.
Mechanism
Binds centrally to calcitonin receptor-RAMP complexes to decrease postprandial glucagon secretion, slow gastric emptying, and promote mealtime satiety signaling.
Dosing
Published experimental protocols outline an initial microgram-scale starting dose of 15 mcg administered subcutaneously prior to major feeding events.
Reconstitution
Reconstituting a 5 mg vial with 2.5 mL of bacteriostatic water creates a final solution concentration of 2 mg/mL (2,000 mcg/mL).
Storage
Store unopened lyophilized vials at 2–8°C away from light, and maintain the reconstituted peptide refrigerated without exposure to direct light or sub-freezing conditions.
Mix & measure Pramlintide 5mg
Pre-filled with this protocol's recommended BAC water and documented starting dose — edit any field to run your own numbers.
Mix & measure Pramlintide 5mg
Vial strength → BAC water → target dose
Common vial sizes
Label claim
Total doses in vial: 333.3
U-100 syringe: 100 units = 1 mL
Need supplies for this protocol?
Research-grade peptides, fast shipping, competitive pricing
Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Advanced calculator →
Track my protocol
Log each dose, build a streak, and watch your progress through this protocol's schedule.
Dosing Chart
| Phase / Day(s) | Dose & Frequency | Volume (U-100 units / mL) |
|---|---|---|
| Type 1 — start | 15 mcg per major meal | ~0.75 units (0.0075 mL) |
| Type 1 — target | 30–60 mcg per major meal | 1.5–3 units (0.015–0.03 mL) |
| Type 2 — start | 60 mcg per major meal | 3 units (0.03 mL) |
| Type 2 — target | 120 mcg per major meal | 6 units (0.06 mL) |
Reconstitution Steps
- 1
Thoroughly clean the rubber septums of both the lyophilized peptide vial and the bacteriostatic water container with individual sterile alcohol swabs.
- 2
Draw 2.5 mL of bacteriostatic water into a sterile mixing syringe.
- 3
Insert the needle at a slight angle and dispense the diluent down the glass vial wall, avoiding direct forceful contact with the lyophilized cake.
- 4
Swirl the vial in a gentle circular motion until all peptide solids have dissolved into a clear solution without shaking.
- 5
Record the date of reconstitution on the label and immediately store the reconstituted vial in a laboratory refrigerator at 2–8°C.
Supplies Needed
Peptide Vial
Lyophilized pramlintide powder (5 mg) requiring reconstitution.
Insulin Syringes (U-100)
Ultra-fine calibrated syringes required for accurate low-volume microgram aliquots.
Bacteriostatic Water
Preserved sterile diluent (2.5 mL required) for peptide dissolution.
Alcohol Swabs
Antiseptic preparation of vial tops and injection contact points.
Why researchers study it
Post-meal glucose control
Body-weight endpoints
Amylin + incretin combinations
Appetite and satiety signaling
These describe what is being studied, not proven benefits, approved uses, or promised results.
Overview
Pramlintide is a laboratory-engineered synthetic analogue of human amylin, an endogenous neuroendocrine hormone produced and released alongside insulin by pancreatic beta cells. In natural human physiology, native amylin readily forms insoluble amyloid fibrils, rendering it unstable for therapeutic and sustained laboratory deployment; pramlintide overcomes this pharmaceutical limitation through targeted proline substitutions that retain native receptor binding capacity while entirely preventing self-aggregation. In preclinical and clinical metabolic modeling, pramlintide is extensively explored for its capacity to blunt postprandial glycemic excursions without directly stimulating insulin release. By mimicking native islet amyloid polypeptide activity within specialized central autonomic networks, it exerts coordinated influence over the rate of nutrient passage from the stomach, suppressive regulation of inappropriate post-meal glucagon secretion, and neurochemical satiety signaling. Investigational protocols frequently evaluate its behavior both as a stand-alone regulator of energy intake and as an experimental co-agent alongside modern incretin mimetics.
References
- 1.FDA, Prescribing Information, 2015 — SYMLIN (pramlintide acetate) official label and clinical guidelines
- 2.Ryan et al., Clin Ther, 2005 — Pramlintide pharmacology and proline substitution mechanism in diabetes
- 3.Whitehouse et al., Diabetes Care, 2002 — 52-week trial of pramlintide as insulin adjunct in type 1 diabetes
- 4.Hollander et al., Diabetes Care, 2003 — 1-year randomized trial of pramlintide in insulin-treated type 2 diabetes
- 5.Aronne et al., J Clin Endocrinol Metab, 2007 — Phase 2 dose-escalation of pramlintide for non-diabetic obesity
- 6.Hay et al., Pharmacol Rev, 2015 — Comprehensive pharmacology and physiology of amylin receptor signaling
- 7.Enebo et al., Lancet, 2021 — Dual amylin and GLP-1 agonism combining cagrilintide with semaglutide
- 8.NIDDK / NCBI Bookshelf, LiverTox, 2019 — Clinical summary of pramlintide mechanisms and adverse effects
Supplies Needed
Suggested supplier
Research use only. Listing a supplier is not an endorsement of any protocol on this site, and nothing sold there is approved for human use.
Related protocols
View allCartalax 20mg
Synthetic short bioregulator tripeptide (AED) explored in vitro for cartilage integrity, collagen synthesis, and cellular aging.
View ProtocolGLOW (GHK-Cu + TB-500 + BPC-157)
A 70 mg multi-peptide research formulation combining GHK-Cu, TB-500, and BPC-157 in a fixed 5:1:1 ratio for tissue repair investigations.
View ProtocolL-Carnitine 200mg
An amino-acid derivative researched for mitochondrial fatty-acid shuttling, metabolic energy pathways, and exercise recovery dynamics.
View Protocol